Skip to main content
RPRX logo

RPRX · Royalty Pharma plc

Track RPRX — free
$68.44 -0.24 (-0.35%)
Market Cap
$39.40B
Shares
573.61M
Volume · Nov 18 539.86K Avg daily vol (3M) 3.17M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$68.68 Open$67.92 Day$67.62–68.77 52W close$38.09–70.01 Avg vol 30d3.4M Short int13.1M · 2.3% of shares · 4.0d Short vol37% Last earningsNov 4, 2026 DataJun 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 10, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 17
Investor event
Third-quarter beat and raise; 480 opportunities reviewed last year

Royalty Pharma reported a third-quarter beat and raise. Last year it looked at 480 opportunities and did about seven deals for $4.7 billion in announced transaction value. Its publicly stated goal is $2 to $2.5 billion a year in capital deployment, and management said those figures will go up over time as big pharma co-funding deals grow.

4 source passages
We just announced another beat on the earnings and raise. Last year, we looked at 480 opportunities. I think we did about seven deals for about $4.7 billion in announced transaction value. publicly stated goals of $2 to $2.5 billion a year those numbers will go up over time, much as the overall R&D budgets for big pharma, big biotech continue to grow. Open the document at this passage
Nov 4
Earnings call
2026 portfolio receipts guidance raised for third consecutive quarter

Royalty Pharma raised 2026 portfolio receipts guidance to $3.5 billion to $3.55 billion from $3.4 billion to $3.5 billion, citing 10% to 11% royalty-receipt growth expected versus 7% to 10% previously.

3 source passages
Welcome to the Royalty Pharma Third Quarter 2026 Earnings Conference Call. We now expect portfolio receipts to be in the range of $3.5 billion to $3.55 billion, up from $3.4 billion to $3.5 billion previously. This assumes growth in royalty receipts of around 10% to 11%, compared with 7% to 10% previously We've raised our guidance for the third consecutive quarter Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Royalty income rises 12.7%, but net income falls 17.7%

Royalty Pharma plc reported first-nine-month income from financial royalty assets of $1,880,627 thousand in 2026, up 12.7%, as net income attributable to the company fell 17.7% to $457,248 thousand.

Revenue $690.1M ▲ 13.3% Net income $144.68M ▼ 49.1% Diluted EPS $0.32 ▼ 51.5%
Read from the MD&A section
3 source passages
Income from financial royalty assets increased by $211.9 million, or 12.7%, in the first nine months of 2026 as compared to the first nine months of 2025, primarily driven by increases in interest income from Tremfya and the cystic fibrosis franchise, as well as $76.9 million of interest income from Imdelltra, which was acquired in the third quarter of 2025 and is reflected within other products in the table above. | Total income from financial royalty assets | 647,608 | 578,812 | 68,796 | 11.9 | 1,880,627 | 1,668,720 | 211,907 | 12.7 | | Net income attributable to Royalty Pharma plc | 144,675 | 284,217 | (139,542) | (49.1) | 457,248 | 555,742 | (98,494) | (17.7) | Open the document at this passage
Nov 4
Current report 8-K
Portfolio Receipts rose 9%; guidance raised

Royalty Pharma plc reported third-quarter Portfolio Receipts of $890 million, up 9%, and raised full-year 2026 Portfolio Receipts guidance to $3,500 million to $3,550 million from $3,400 million to $3,500 million.

Financial results
3 source passages
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. Portfolio Receipts increased by 9% to $890 million, reflecting higher milestones and other contractual receipts. Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,500 million and $3,550 million (previously $3,400 million to $3,500 million), representing expected Royalty Receipts growth of 10% to 11%. Open the document at this passage
Sep 23
Investor event
Royalty Pharma at the BofA Global Healthcare Conference

Royalty Pharma targets $2 to $2.5 billion in annual capital deployment, sees AI enhancing diligence, and is building a China investment team focused on passive royalties; leverage above 4 would require a compelling transaction and rapid deleveraging.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.62B
Trailing 12 months
Net income (TTM)
$672.45M
Trailing 12 months
Revenue growth YoY
+13.3%
Year over year
Operating margin
57.1%
Trailing 12 months
P / E (TTM)
44.9
Trailing earnings · reciprocal yield 2.2%
FCF yield
—
TTM · current market cap
Return on invested capital
8.4%
Trailing 12 months
Net cash
−$8.07B
Latest balance sheet
Dividend yield
1.4%
Trailing 12 months
Shares change YoY
-0.5%
Year over year · fewer shares
Price change (1Y)
+75.4%
Trailing year
Short interest
2.3%
Latest settlement · 4.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Royalty Pharma raised full-year guidance after 9% growth in quarterly Royalty and Portfolio Receipts, added three royalties and reported positive clinical and regulatory progress. Risks include the pelacarsen and Niktimvo trial failures, a $150 million pelacarsen impairment, declining Promacta and Imbruvica receipts, lower operating cash flow and net income, and reduced milestone receipts.

Bullish
  • + Royalty Pharma acquired royalty interests in Zoryve, Mimrylo and cliramitug during the third quarter.
  • + Royalty Pharma announced $1 billion of R&D co-funding deals during 2026 and described additional opportunities in the deal funnel.
  • + Royalty Pharma raised full-year 2026 Portfolio Receipts guidance to $3,500 million–$3,550 million and expects 10%–11% Royalty Receipts growth.
  • + Royalty Pharma reported multiple positive clinical and regulatory developments across its royalty portfolio.
Bearish
  • − The pelacarsen Phase 3 trial missed its primary endpoint, and Royalty Pharma recorded a $150 million non-cash impairment.
  • − Niktimvo failed to meet the primary endpoint of its Phase 2 MAXPIRe trial in idiopathic pulmonary fibrosis, and Syndax will not advance it in that indication.
  • − Net cash provided by operating activities declined 2%, to $686 million from $703 million.
  • − Milestones and other contractual receipts are expected to decrease to approximately $65 million in 2026 from $128 million in 2025.
  • − Promacta and Imbruvica receipts declined, partly offsetting growth from Tremfya, Voranigo, Evrysdi and Imdelltra.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very Low
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +25%
above
Price vs 50-day avg +11%
above
RSI (14) 67
neutral
MACD trend Negative
52-week position 96%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +10%
trailing
6-month return +26%
trailing
YTD return +78%
this year
Relative strength +29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $62 › 200d $55 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +108 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.28% of shares out · ▲ +1.8% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
706 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Fair
Revenue growth +5%
Y/Y
EPS growth −7%
Y/Y
Valuation P/E 44.9
below peers
Buyback $1.6B
remaining
Balance sheet $8.3B
net debt
Quant / Vol
risk profile
Very Low
Volatility 22%
annualized · 1-yr
Max drawdown −12%
past year
ATR 2.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 0 of last 2
Latest guidance · from the 8-K filed Nov 4, 2026
full year 2026
Portfolio Receipts Raised $3.5B – $3.55B
Aug 5, 2026 $3.4B – $3.5B changed to Nov 4, 2026 $3.5B – $3.55B
Payments for operating and professional costs Lowered 5.5% – 6%
Aug 5, 2026 5.5% – 6.5% changed to Nov 4, 2026 5.5% – 6%
2026
Interest paid Maintained $350M – $360M
Aug 5, 2026 $350M – $360M changed to Nov 4, 2026 $350M – $360M
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Portfolio receipts · full year 2026 $3.4B – $3.5B
Royalty receipts · full year 2026 7% – 10%
Portfolio receipts · by 2030 $4.7B
Milestones and other contractual receipts · for the year $60M
Prior guidance period ended · from the Earnings Call filed Aug 5, 2026
Interest paid · third quarter 2026 $175M
Guided vs delivered · last 2 settled
Portfolio receipts second quarter 2026
guided $740M – $760M
$674.14M Miss −10.1%
Portfolio Receipts full year 2025
guided $3.05B – $3.15B
$2.38B Miss −23.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+25% Bullish
Price vs 50-day avg
+11% Bullish
RSI (14)
67 Neutral
MACD trend
Negative Bearish
52-week position
96% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $62 › 200d $55 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +108 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.28% of shares out · ▲ +1.8% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
706 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $38 Now $69 · 96% Range high $70
vs 200-day avg +25% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA (non-GAAP) non-GAAP $736M Q2 2026 —
GAAP → non-GAAP reconciliation
GAAP Portfolio Receipts $773M
-$37M Payments for operating and professional costs
= Adjusted EBITDA (non-GAAP) $736M
Capital Deployment $349M Q2 2026 —
Portfolio Cash Flow (non-GAAP) non-GAAP $736M Q2 2026 —
Portfolio Receipts $772.98M the three months ended June 30, 2026 filing —
Weighted average Class A ordinary shares outstanding - diluted 557M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RPRX
Royalty Pharma plc
this stock
$39.40B +77.7% +5.1% 44.9 2.3%
VRTX
Vertex Pharmaceuticals Inc
$135.44B +17.8% +46.2% 34.4 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$99.08B +24.1% +20.8% 21.2 2.1%
MRNA
Moderna, Inc.
$83.68B +601.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$64.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
706
% held
65.3%
Net QoQ
+7.4M sh
Top holder
MORGAN STANLEY
Held Float
View
Held by Funds
Fund positions
196
View
Short & Settlement
Short Interest Rising
Shares short
13.1M
Days to cover
4.0d
Change
+232.6K sh
View
Short Volume
Short vol %
37%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
54
Value
$3.5K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.4B
Net income (FY)
$770.9M
EPS diluted
$1.78
View
Buybacks
Authorized
$3.0B
Remaining
$1.6B
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
22

Royalty Pharma reported a third-quarter beat and raise. Last year it looked at 480 opportunities and did about seven deals for $4.7 billion in announced transaction value. Its publicly stated goal is $2 to $2.5 billion a year in capital deployment, and management said those figures will go up over time as big pharma co-funding deals grow.

View
Proposed Sales
Value
$235.6K
Shares
4.1K
Filed
Oct 5, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Royalty Pharma reports third quar…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
RPRX -1.1% +10.3% +26.1% +2.2% +77.7%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +1.2% +15.1% +29.0% +5.3% +70.3%

Capital returns

Latest dividend
$0.235 / share · ex Nov 13, 2026
Raised 6.8%
Paid (TTM)
$0.94 / share · 4 payouts
Dividend yield (TTM, derived)
1.37%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$3.00B
Spent (derived)
$1.40B
Remaining
$1.60B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1802768 CUSIP G7709Q104 13F (30d) 687 filings 645 filers Visit website Investor relations